Have a feature idea you'd love to see implemented?
Let us know!
ATYR Atyr Pharma Inc
Price (delayed)
$2.98
Market cap
$250.15M
P/E Ratio
N/A
Dividend/share
N/A
EPS
-$0.94
Enterprise value
$249.33M
atyr pharma (nasdaq: life) is engaged in the discovery and clinical development of innovative medicines for patients suffering from severe rare diseases using its knowledge of physiocrine biology, a newly
Highlights
The debt has contracted by 11% YoY and by 2% from the previous quarter
ATYR's EPS is down by 3.3% since the previous quarter but it is up by 3.1% year-on-year
The company's gross profit has shrunk by 98% YoY and by 60% QoQ
The revenue has shrunk by 98% YoY and by 60% QoQ
Key stats
What are the main financial stats of ATYR
Market
Valuations
Earnings
Shares outstanding
83.94M
Market cap
$250.15M
Enterprise value
$249.33M
Price to earnings (P/E)
N/A
Price to book (P/B)
3.46
Price to sales (P/S)
961.23
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
1,061
Revenue
$235,000
EBIT
-$63.82M
EBITDA
-$61.87M
Free cash flow
-$67.11M
Per share
Balance sheet
Liquidity
EPS
-$0.94
Free cash flow per share
-$0.89
Book value per share
$0.86
Revenue per share
$0
TBVPS
$1.21
Total assets
$91.62M
Total liabilities
$26.48M
Debt
$13.57M
Equity
$65.33M
Working capital
$62.2M
Debt to equity
0.21
Current ratio
5.41
Quick ratio
5.01
Net debt/EBITDA
0.01
Margins
Efficiency
Dividend
EBITDA margin
-26,326.8%
Gross margin
100%
Net margin
-27,155.7%
Operating margin
-28,958.7%
Return on assets
-59.2%
Return on equity
-79.3%
Return on invested capital
-69.1%
Return on capital employed
-82.3%
Return on sales
-27,155.7%
Dividend yield
N/A
DPS
N/A
Payout ratio
N/A
ATYR stock price
How has the Atyr Pharma stock price performed over time
Intraday
-0.33%
1 week
-6.58%
1 month
-8.59%
1 year
161.4%
YTD
111.35%
QTD
69.32%
Financial performance
How have Atyr Pharma's revenue and profit performed over time
Revenue
$235,000
Gross profit
$235,000
Operating income
-$68.05M
Net income
-$63.82M
Gross margin
100%
Net margin
-27,155.7%
The net margin has plunged by 176% from the previous quarter
ATYR's operating margin has dropped by 172% since the previous quarter
The company's gross profit has shrunk by 98% YoY and by 60% QoQ
The revenue has shrunk by 98% YoY and by 60% QoQ
Growth
What is Atyr Pharma's growth rate over time
Valuation
What is Atyr Pharma stock price valuation
P/E
N/A
P/B
3.46
P/S
961.23
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
1,061
ATYR's EPS is down by 3.3% since the previous quarter but it is up by 3.1% year-on-year
ATYR's P/B is 189% above its 5-year quarterly average of 1.2 and 131% above its last 4 quarters average of 1.5
The company's equity fell by 34% YoY and by 20% QoQ
The revenue has shrunk by 98% YoY and by 60% QoQ
Efficiency
How efficient is Atyr Pharma business performance
ATYR's ROS has dropped by 176% since the previous quarter
The return on equity has dropped by 77% year-on-year and by 22% since the previous quarter
The company's return on invested capital has shrunk by 71% YoY and by 21% QoQ
The ROA has plunged by 68% YoY and by 19% from the previous quarter
Dividends
What is ATYR's dividend
DPS
N/A
Dividend yield
N/A
Payout ratio
N/A
There are no recent dividends present for ATYR.
Financial health
How did Atyr Pharma financials performed over time
Atyr Pharma's quick ratio has decreased by 40% YoY and by 29% from the previous quarter
The current ratio has contracted by 35% YoY and by 29% from the previous quarter
The debt is 79% less than the equity
ATYR's debt to equity is up by 40% YoY and by 24% from the previous quarter
The company's equity fell by 34% YoY and by 20% QoQ
All financial data is based on trailing twelve months (TTM) periods - updated quarterly, unless otherwise
specified. Data from 
and Sharadar.